Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer has officially closed on its $10 billion purchase of obesity drug maker Metsera. So what does everyone think of the ...

Investing.com -- Pfizer Inc plans to expand its obesity portfolio globally with a focus on oral medications following its Metsera acquisition, Chief Financial Officer Dave Denton said at the Jefferies ...

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the ...

Pfizer offers strong dividends, solid cash flow coverage, discounted value and key risks from patent cliffs, pricing and ...

Pfizer Inc. has announced the successful completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical ...

Now, it’s worth noting Stock Advisor’s total average return is 1,035% — a market-crushing outperformance compared to 191 % ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Just one month into his job, Novo Nordisk’s new chief executive went to bed one night in September thinking he had secured a ...

Pfizer Inc. ($PFE) is returning to the U.S. debt markets with a fresh corporate bond offering aimed at raising at least $5 ...

Pfizer Inc (NYSE:PFE) is preparing to broaden its presence in the global obesity market, with a particular emphasis on ...